Patent application number | Description | Published |
20110269767 | Novel Polymorphic Forms of 3-(1--6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile Hydrochloride Salt and Processes of Manufacturing Thereof - The present invention relates to 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride solvates and crystalline modifications thereof. The present invention further relates to processes of manufacturing these crystalline modifications as well as their use in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions, which are caused, mediated and/or propagated by the inhibition, regulation and/or modulation of signal transduction of kinases, in particular by the inhibition of tyrosine kinases, e.g. pathophysiological conditions such as cancer. | 11-03-2011 |
20140200221 | NOVEL POLYMORPHIC FORMS OF 3-(1--6-OXO-1,6-DIHYDRO-PYRIDAZIN-3-YL)-BENZONITRILE HYDROCHLORIDE SALT AND PROCESSES OF MANUFACTURING THEREOF - The present invention relates to 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride solvates and crystalline modifications thereof. The present invention further relates to processes of manufacturing these crystalline modifications as well as their use in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions, which are caused, mediated and/or propagated by the inhibition, regulation and/or modulation of signal transduction of kinases, in particular by the inhibition of tyrosine kinases, e.g. pathophysiological conditions such as cancer. | 07-17-2014 |
Patent application number | Description | Published |
20100058121 | VISUALIZATION OF USER INTERACTIONS IN A SYSTEM OF NETWORKED DEVICES - As set forth herein, a system identifies soft failures of devices. An interface captures transactional data between one or more users and one or more devices within the system. A data log receives the transactional data from the interface and stores the data as historical data for subsequent retrieval. A warning system evaluates the historical data in the data log to identify one or more devices that have a soft failure condition, wherein an alarm is output for each soft failure identified. A display module combines the historical data from the data log and one or more alarms from the warning system into a single display for review. | 03-04-2010 |
20100145647 | SYSTEM AND METHOD FOR IMPROVING FAILURE DETECTION USING COLLECTIVE INTELLIGENCE WITH END-USER FEEDBACK - Systems and methods are described that facilitate using end-user feedback to automatically distinguish between a normal behavior and a device failure which can be a hard failure (e.g., a device malfunction) or a soft failure. For instance, upon detection of a usage switch from a first device to a second device by a user, a survey message is sent to the user to solicit information regarding the reasons for the switch. If the switch was triggered by a device malfunction, the detected device failure is verified and an alert is sent to an administrator and/or potentially impacted users. If the switch was triggered by the user's need for functionality (e.g., color printing, collation, etc.) not provided by the first device, which is otherwise functioning properly, then the detected failure is determined to be a failure and the failure detection algorithm is updated accordingly. | 06-10-2010 |
20110010571 | PRINTER TIME-OUT - A system and a method of providing a time-out for a device, such as a printer are provided. The time-out determines when the device is shifted from a higher energy to a lower energy mode, absent the arrival of another job to be processed by the device. The method includes acquiring data comprising a set of inter-arrival times for at least one device over a period of time, such as a week and, for each of a set of candidate time-outs, deriving a probability from the data that an inter-arrival time from the set of inter-arrival times is greater than the candidate time-out. A cost function is computed, based on the derived probability and a robustness term which allows adversarial action not predicted by the histogram to be taken into account. A time-out for the at least one device can then be identified for which the cost function is a minimum. | 01-13-2011 |
Patent application number | Description | Published |
20090186824 | NOVEL PEPTIDES FOR TREATING AND PREVENTING IMMUNE-RELATED DISORDERS, INCLUDING TREATING AND PREVENTING INFECTION BY MODULATING INNATE IMMUNITY - In one aspect, the present invention provides isolated novel peptides that can be used to modulate innate immunity in a subject and/or for the treatment of an immune-related disorder, including treating and preventing infection by modulating innate immunity. Also provided are an agent reactive with the peptide, a pharmaceutical composition that includes the peptide, an isolated nucleic acid molecule encoding the peptide, a recombinant nucleic acid construct that includes the nucleic acid molecule, at least one host cell comprising the recombinant nucleic acid construct, and a method of producing the peptide using the host cell. The present invention further provides a method for treating and/or preventing infection in a subject by administering the peptide of the invention to the subject, thereby modulating innate immunity in the subject. Additionally, the present invention provides a method for predicting whether a subject would be responsive to treatment with a peptide of the invention. | 07-23-2009 |
20090246217 | Novel Peptides for Treating and Preventing Immune-Related Disorders, Including Treating and Preventing Infection by Modulating Innate Immunity - In one aspect, the present invention provides isolated novel peptides that can be used to modulate innate immunity in a subject, and/or for the treatment of an immune-related disorder, including treating and preventing infection by modulating innate immunity. Also provided are an agent reactive with this peptide, a pharmaceutical composition that includes the peptide, an isolated nucleic acid molecule encoding the peptide, a recombinant nucleic acid construct that includes the nucleic acid molecule, at least one host cell comprising the recombinant nucleic acid construct, and a method of producing the peptide using the host cell. The present invention further provides a method for treating and/or preventing infection in a subject by administering the peptide of the invention to the subject, thereby modulating innate immunity in the subject. Additionally, the present invention provides a method for predicting whether a subject would be responsive to treatment with a peptide of the invention. | 10-01-2009 |
20130224231 | NOVEL PEPTIDES FOR TREATING AND PREVENTING IMMUNE-RELATED DISORDERS, INCLUDING TREATING AND PREVENTING INFECTION BY MODULATING INNATE IMMUNITY - In one aspect, the present invention provides isolated novel peptides that can be used to modulate innate immunity in a subject and/or for the treatment of an immune-related disorder, including treating and preventing infection by modulating innate immunity. Also provided are an agent reactive with the peptide, a pharmaceutical composition that includes the peptide, an isolated nucleic acid molecule encoding the peptide, a recombinant nucleic acid construct that includes the nucleic acid molecule, at least one host cell comprising the recombinant nucleic acid construct, and a method of producing the peptide using the host cell. The present invention further provides a method for treating and/or preventing infection in a subject by administering the peptide of the invention to the subject, thereby modulating innate immunity in the subject. Additionally, the present invention provides a method for predicting whether a subject would be responsive to treatment with a peptide of the invention. | 08-29-2013 |
20130316960 | Novel Peptides For Treating and Preventing Immune-Related Disorders, Including Treating And Preventing Infection by Modulating Innate Immunity - In one aspect, the present invention provides isolated novel peptides that can be used to modulate innate immunity in a subject and/or for the treatment of an immune-related disorder, including treating and preventing infection by modulating innate immunity. Also provided are an agent reactive with the peptide, a pharmaceutical composition that includes the peptide, an isolated nucleic acid molecule encoding the peptide, a recombinant nucleic acid construct that includes the nucleic acid molecule, at least one host cell comprising the recombinant nucleic acid construct, and a method of producing the peptide using the host cell. The present invention further provides a method for treating and/or preventing infection in a subject by administering the peptide of the invention to the subject, thereby modulating innate immunity in the subject. Additionally, the present invention provides a method for predicting whether a subject would be responsive to treatment with a peptide of the invention. | 11-28-2013 |